TP方案聯合回生口服液治療中晚期非小細胞肺癌的療效觀察

楊莉

摘 要：目的 探討紫杉醇+順鉑化療方案聯合回生口服液治療中晚期NSCLC的療效。方法 選取2014年1月～2017年5月于我院就診的中晚期NSCLC患者68例，隨機分為觀察組和對照組，每組34例。對照組予以TP方案（紫杉醇+順鉑）治療，觀察組予以TP方案聯合回生口服液治療，對比兩組患者的臨床療效、不良反應、血清VEGF、IL-6、MMP-9水平和生存時間、生活質量。結果 觀察組的治療總有效率為70.59%，高于對照組的55.89%，差異具有統計學意義（P<0.05）。觀察組治療后的VEGF、IL-6、MMP-9水平均低于對照組，差異具有統計學意義（P<0.05）。觀察組治療后的生活質量評分高于對照組，差異具有統計學意義（P<0.05）。觀察組的腫瘤進展時間為（5.46±2.76）個月、生存時間（11.04±0.82）個月，少于對照組的腫瘤進展時間為（4.15±2.15）個月、生存時間（8.12±0.64）個月（Log Rank： statistic=4.15，P=0.037）。觀察組不良反應率為20.59%，低于對照組的41.18%，差異具有統計學意義（P<0.05）。結論 TP方案聯合回生口服液治療中晚期NSCLC的臨床療效良好，可有效改善中晚期NSCLC患者的炎癥狀態，抑制腫瘤心血管生成，提高腫瘤細胞殺傷能力，臨床療效顯著，安全性高，患者治療后的生存期有效延長，生活質量明顯提高。

關鍵詞：非小細胞肺癌；TP方案；回生口服液

中圖分類號：R734.2 文獻標識碼：A DOI：10.3969/j.issn.1006-1959.2018.17.005

文章編號：1006-1959（2018）17-0017-03

Abstract：Objective To investigate the efficacy of paclitaxel+cisplatin chemotherapy combined with Huisheng oral liquid in the treatment of advanced NSCLC.Methods A total of 68 patients with advanced NSCLC who were admitted to our hospital from January 2014 to May 2017 were randomly divided into observation group and control group，with 34 cases in each group.The control group was treated with TP regimen（paclitaxel+cisplatin），and the observation group was treated with TP regimen combined with Huisheng oral liquid.The clinical efficacy，adverse reactions，serum VEGF，IL-6，MMP-9 levels，survival time and quality of life were compared between the two groups.Results The total effective rate of the observation group was 70.59%，which was higher than that of the control group 55.89%，the difference was statistically significant（P<0.05）.The levels of VEGF，IL-6 and MMP-9 in the observation group were lower than those in the control group，the difference was statistically significant（P<0.05）.The quality of life scores of the observation group after treatment were higher than those of the control group，the difference was statistically significant（P<0.05）.The tumor progression time of the observation group was（5.46±2.76）months and survival time（11.04±0.82）months，and the tumor progression time was less than（4.15±2.15）months and survival time（8.12±0.64）month（Log Rank：statistic=4.15，P= 0.037）.The adverse reaction rate of the observation group was 20.59%，which was lower than that of the control group 41.18%and the difference was statistically significant（P<0.05）.Conclusion TP regimen combined with Huisheng oral liquid is effective in the treatment of advanced NSCLC.It can effectively improve the inflammatory state of patients with advanced NSCLC，inhibit tumor cardiovascular production，improve tumor cell killing ability，clinical efficacy is significant，and safety is high.After treatment the survival period is effectively extended and the quality of life is significantly improved.

Key words：Non-small cell lung carcinoma；TP regimen；Huisheng oral liquid

肺癌（lung cancer）是臨床上最常見的惡性腫瘤之一，發病率較高，嚴重危及我國人民身體健康和生命安全。據調查，非小細胞肺癌（non-small cell lung carcinoma，NSCLC）發病率約占肺癌發病率的80%[1]。NSCLC早期無特異性癥狀，導致許多患者確診時已經屬于中晚期，失去手術治療的機會，對于此類患者多采用化療為主的綜合方式治療[2]。紫杉醇+順鉑化療方案（docetaxel combined cisplatin，TP）是治療肺癌的常用化療方案，能夠有效緩解病情進展，延長患者的生存時間，但是在化療藥物殺死患者癌細胞的同時會損傷正常細胞，導致患者出現一系列的不良反應，影響患者的治療效果[3]。回生口服液是一種中成藥，具有抗腫瘤作用，能夠殺死腫瘤細胞[4]。因此，本研究對2014年1月～2017年5月于我院就診的34例中晚期NSCLC患者實施TP方案聯合回生口服液治療，以期為臨床治療提供參考依據，現報道如下。

1資料與方法

1.1一般資料 選取2014年1月～2017年5月于四川省江油市人民醫院就診的中晚期NSCLC患者68例作為研究對象，本研究經醫院倫理會批準。……